# VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer

> **NCT00003847** · PHASE2 · TERMINATED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 36 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** biricodar dicitrate
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00003847
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1998-12
- **Primary completion:** 2001-02
- **Final completion:** —
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003847, "VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00003847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*